1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Lupin Limited
  6. Company
    LUPIN   INE326A01037

LUPIN LIMITED

(LUPIN)
  Report
Delayed NSE India Stock Exchange  -  07:23 2022-07-04 am EDT
628.30 INR    0.00%
06/30Lupin Gets US FDA Nod for Paliperidone Extended-Release Tablets
MT
06/30LUPIN : June 30, 2022 Lupin Receives Approval from U.S. FDA for Paliperidone Extended-Release Tablets
PU
06/30Lupin Limited Receives Approval from U.S. FDA for Paliperidone Extended-Release Tablets
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:

- design and production of generic and brand-name formulations;

- production of active pharmaceutical ingredients.

At the end of March 2020, the group had 15 production sites India (12), the United States, Mexico and Brazil.

Net sales break down geographically as follows: India (37.3%), the United States (37.2%), Japan (0.7%) and other (24.8%).
Sales per Business
20202021Delta
Pharmaceutical Goods149 892.0097.5%149 139.0098.4% -0.5%
Export Benefits and Other Incentives2 086.201.4%1 173.500.8% -43.75%
Business Compensation and Settlement77.600.1%827.200.5% +965.98%
Insurance Claims42.30-206.600.1% +388.42%
Research Services1 536.201%130.900.1% -91.48%
Miscellaneous84.000.1%127.400.1% +51.67%
Service Charges29.50-25.00- -15.25%
INR in Million
Sales per region
20202021Delta
India58 647.5038.1%59 316.9039.1% +1.14%
United States56 431.5036.7%54 023.1035.6% -4.27%
Others37 578.5024.4%36 015.0023.8% -4.16%
Japan1 090.100.7%2 274.601.5% +108.66%
INR in Million
Managers
Name Title Age Since
Vinita D. Gupta Chief Executive Officer & Executive Director 54 2014
Ramesh Swaminathan Global CFO & Executive Director - 2020
Alok Sonig CEO-US Generics, Head-Biosimilars, Global R&D - -
Johnny Mikell President-Global Quality & Compliance - -
Rajvardhan V. Satam Secretary - -
Nilesh Deshbandhu Gupta Managing Director & Executive Director 47 2013
Debabrata Chakravorty President-Global Sourcing & Contract Manufacturing - -
Rajender Kamboj, Dr. President-Novel Drug Discovery & Development - -
Cyrus Karkaria, Dr. President-Biotechnology - -
Naresh Gupta President-Active Pharmaceutical Ingredients - -
Members of the board
Name Title Age Since
Manju Deshbandhu Gupta Non-Executive Chairman 78 2017
Jean-Luc Bélingard Independent Non-Executive Director 72 2015
Christine Ann Mundkur Independent Non-Executive Director 52 2019
Mark D. McDade Independent Non-Executive Director 65 2021
K. B. S. Anand Independent Non-Executive Director 65 2020
Kamal Kishore Sharma Non-Executive Vice Chairman 73 2013
Nilesh Deshbandhu Gupta Managing Director & Executive Director 47 2013
Vinita D. Gupta Chief Executive Officer & Executive Director 54 2014
Ramesh Swaminathan Global CFO & Executive Director - 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 454,552,687 240,878,287 53.0% 0 0.0% 53.0%
Shareholders
NameEquities%
Lupin Investments Pvt Ltd. 205,770,835 45.3%
Life Insurance Corporation of India (Investment Portfolio) 38,123,322 8.39%
ICICI Prudential Asset Management Co. Ltd. 23,069,847 5.08%
HDFC Asset Management Co. Ltd. (Invt Mgmt) 19,818,333 4.36%
The Vanguard Group, Inc. 7,462,515 1.64%
SBI Funds Management Pvt Ltd. 6,794,269 1.49%
Norges Bank Investment Management 6,039,098 1.33%
BlackRock Fund Advisors 5,364,740 1.18%
Franklin Templeton Asset Management (India) Pvt. Ltd. 4,924,266 1.08%
Nippon Life India Asset Management Ltd. (Invt Mgmt) 4,815,896 1.06%
Markets and indexes
- Main Market
Stock Exchange Codes
- Bloomberg Code :  LUPIN:IN
- Reuters Code :  LUPIN.BO
- Datastream Code :  
Company contact information
Lupin Limited
B/4 Laxmi Towers, Bandra Kurla Complex
IN-400 051 Mumbai, Maharashtra

Phone : +91 22 6640 2222
Fax : +91 22 6640 2130
web site : http://www.lupinworld.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Lupin Limited
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
LUPIN LIMITED-33.92%3 621
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782
NOVO NORDISK A/S6.75%248 942
MERCK & CO., INC.20.59%233 712
ASTRAZENECA PLC23.55%200 459
NOVARTIS AG0.06%181 232
BRISTOL-MYERS SQUIBB COMPANY23.24%163 597
AMGEN INC.9.15%131 173
SANOFI10.09%126 838
GSK PLC11.14%108 701
BAYER AG22.02%58 604
DAIICHI SANKYO CO., LTD.15.42%47 859
TAKEDA PHARMACEUTICAL COMPANY LIMITED19.83%42 912
CHUGAI PHARMACEUTICAL CO., LTD-6.93%42 276
JIANGSU HENGRUI MEDICINE CO., LTD.-18.81%37 069
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-19.15%31 582
ASTELLAS PHARMA INC.10.05%27 816